JP2013545761A5 - - Google Patents

Download PDF

Info

Publication number
JP2013545761A5
JP2013545761A5 JP2013541060A JP2013541060A JP2013545761A5 JP 2013545761 A5 JP2013545761 A5 JP 2013545761A5 JP 2013541060 A JP2013541060 A JP 2013541060A JP 2013541060 A JP2013541060 A JP 2013541060A JP 2013545761 A5 JP2013545761 A5 JP 2013545761A5
Authority
JP
Japan
Prior art keywords
seq
vaccine
vaccine formulation
composition
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013541060A
Other languages
English (en)
Japanese (ja)
Other versions
JP6055776B2 (ja
JP2013545761A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/062120 external-priority patent/WO2012074881A2/en
Publication of JP2013545761A publication Critical patent/JP2013545761A/ja
Publication of JP2013545761A5 publication Critical patent/JP2013545761A5/ja
Application granted granted Critical
Publication of JP6055776B2 publication Critical patent/JP6055776B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013541060A 2010-11-24 2011-11-23 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法 Expired - Fee Related JP6055776B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41708910P 2010-11-24 2010-11-24
US61/417,089 2010-11-24
PCT/US2011/062120 WO2012074881A2 (en) 2010-11-24 2011-11-23 Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Publications (3)

Publication Number Publication Date
JP2013545761A JP2013545761A (ja) 2013-12-26
JP2013545761A5 true JP2013545761A5 (enExample) 2015-01-22
JP6055776B2 JP6055776B2 (ja) 2016-12-27

Family

ID=46172477

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013541060A Expired - Fee Related JP6055776B2 (ja) 2010-11-24 2011-11-23 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法

Country Status (6)

Country Link
US (1) US9782474B2 (enExample)
EP (1) EP2643014A4 (enExample)
JP (1) JP6055776B2 (enExample)
AU (1) AU2011336894B2 (enExample)
CA (1) CA2856697A1 (enExample)
WO (1) WO2012074881A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102458463B (zh) 2009-05-22 2017-01-18 健诺西生物科学公司 针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法
CA2856697A1 (en) * 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
JP6199878B2 (ja) * 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
US10011013B2 (en) * 2015-03-30 2018-07-03 X Development Llc Cloud-based analysis of robotic system component usage
WO2017134061A1 (en) * 2016-02-01 2017-08-10 Gu Ventures Ab Truncated glycoprotein g of herpes simplex virus 2
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes
WO2021015987A1 (en) 2019-07-19 2021-01-28 Merck Sharp & Dohme Corp. Antigenic glycoprotein e polypeptides, compositions, and methods of use thereof

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818694A (en) 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
NZ209308A (en) 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US7264817B1 (en) 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
US5244792A (en) 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5612041A (en) 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5149529A (en) 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
EP0471778A1 (en) 1989-05-12 1992-02-26 Ciba Corning Diagnostics Corp. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
CA2088600C (en) 1990-08-02 1999-11-16 Rae L. Burke Herpes simplex virus vp16 vaccines
DK31991D0 (da) 1991-02-25 1991-02-25 Carlbiotech Ltd As Peptid og farmaceutisk praeparat indeholdende et saadant peptid
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5679348A (en) * 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
US5955088A (en) * 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
CA2164601A1 (en) 1993-06-08 1994-12-22 Kevin R. Steffy Herpes simplex virus type-2 protease
MXPA94006367A (es) 1993-08-20 2004-09-09 Smithkline Beecham Corp Gene novedoso.
GB9325496D0 (en) 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
US7094767B2 (en) 1994-07-22 2006-08-22 Merck & Co., Inc. Polynucleotide herpes virus vaccine
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
US5807557A (en) * 1994-07-25 1998-09-15 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US6197497B1 (en) 1995-04-21 2001-03-06 University Of New Mexico Immunoassay for herpes simplex virus
US5654174A (en) 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
US5876923A (en) 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
JP2002514056A (ja) 1996-10-23 2002-05-14 アメリカン・ホーム・プロダクツ・コーポレーション ワクチン
EP0948508A4 (en) 1996-11-04 2001-11-07 Smithkline Beecham Corp NEW CODING SEQUENCES FOR HERPES SIMPLEX TYPE 2 VIRUS
EP0984790A1 (en) 1997-06-02 2000-03-15 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
US6054131A (en) 1998-01-16 2000-04-25 University Of Maryland Baltimore Vaccine composition for herpes simplex virus and method of using
DE69933200T2 (de) 1998-03-09 2007-02-22 Glaxosmithkline Biologicals S.A. Kombinierte impfstoffzusammensetzungen
IL141044A0 (en) 1998-08-07 2002-02-10 Univ Washington Innunological herpes simplex virus antigens and methods for use thereof
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
PL210451B1 (pl) 1999-06-10 2012-01-31 Merial Sas Szczepionka DNA przeciwko wirusowi nosówki psów (CDV)
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
AU782676B2 (en) 1999-09-30 2005-08-18 Corixa Corporation Immunologically significant herpes simplex virus antigens
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
ATE319833T1 (de) 1999-12-17 2006-03-15 Wyeth Corp Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US6821519B2 (en) 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20030165819A1 (en) 2000-06-29 2003-09-04 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
WO2002002131A2 (en) 2000-06-29 2002-01-10 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6682892B2 (en) 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
ATE381351T1 (de) 2000-07-27 2008-01-15 Univ Pennsylvania Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten
EP1178111A1 (en) * 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
JP2005510489A (ja) 2000-11-16 2005-04-21 ユニバーシティ オブ メリーランド，ボルチモア 再発性のウイルス性疾患の予防
US6867000B2 (en) 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
WO2003011893A2 (en) 2001-07-31 2003-02-13 University Of Washington Immunologically significant herpes simplex virus antigens and methods for using same
AU2002323443A1 (en) 2001-09-04 2003-03-18 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20030219448A1 (en) 2002-05-24 2003-11-27 Cedars-Sinai Medical Center Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases
US20080299140A1 (en) 2002-05-24 2008-12-04 The Regents Of The University Of California, Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition
AU2003252052A1 (en) 2002-07-18 2004-02-09 University Of Washington Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
US7267940B2 (en) 2003-03-04 2007-09-11 Bio-Rad Laboratories, Inc. HSV-2 type-specific immunoassays using glycoprotein G2 peptides
EP2289547B1 (en) 2003-09-12 2015-12-16 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
CA2630218A1 (en) 2005-11-18 2007-08-30 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
EP2001516A4 (en) 2006-03-10 2010-04-28 Univ California VACCINATES AGAINST PERSISTENT OR LATENT INFECTIONS THREADING VIRUSES
CA2658484A1 (en) 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
US20090246220A1 (en) 2006-08-28 2009-10-01 Ertl Hildegund C J Constructs for enhancing immune responses
CN101583381B (zh) 2006-09-08 2014-05-07 宾夕法尼亚大学董事会 Hsv-1和hsv-2疫苗和其使用方法
EP2087128A4 (en) 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
US8057804B2 (en) 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
AU2007342345B9 (en) 2006-12-28 2013-09-12 The Trustees Of The University Of Pennsylvania Herpes Simplex Virus combined subunit vaccines and methods of use thereof
US7785605B2 (en) 2007-07-05 2010-08-31 University Of Kansas Herpes simplex virus mutant ICP0 protein
WO2009006680A1 (en) 2007-07-06 2009-01-15 Sydney West Area Health Service Epitopes of herpes simplex virus
AU2009266924B2 (en) 2008-07-01 2015-12-10 Genocea Biosciences, Inc. Antigen screening system
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
EP2379106A4 (en) 2008-12-17 2012-06-13 Genocea Biosciences Inc ANTIGENS OF CHLAMYDIAS AND USES THEREOF
US8460674B2 (en) * 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
US20120100171A1 (en) 2009-03-09 2012-04-26 William Henry Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions
CN102458463B (zh) * 2009-05-22 2017-01-18 健诺西生物科学公司 针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法
US9089537B2 (en) * 2010-02-26 2015-07-28 The Trustees Of The University Of Pennslyvania Subunit vaccines for herpes viruses and methods of use
CA2792679C (en) 2010-03-09 2019-11-12 Mucosal Vaccine Thechnologies Llc A novel mucosal vaccination approach for herpes simplex virus type-2
CA2849391A1 (en) 2010-10-20 2012-04-26 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
CA2856697A1 (en) * 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
JP6199878B2 (ja) 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法

Similar Documents

Publication Publication Date Title
JP7792339B2 (ja) コロナウイルスワクチン製剤
Vasireddy et al. Review of COVID-19 vaccines approved in the United States of America for emergency use
KR20220154121A (ko) 코로나바이러스 면역원성 조성물 및 이의 용도
CN109843323B (zh) 用于黄病毒疫苗接种的组合物和方法
CN101616688B (zh) 单纯疱疹病毒联合亚单位疫苗及其使用方法
JP6096839B2 (ja) 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物および方法
JP2022547313A (ja) ヒトサイトメガロウイルスワクチン
JP2012527486A5 (enExample)
CN113666990B (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
JP2023512648A5 (enExample)
CN113454102A (zh) 非洲猪瘟疫苗
EP3302543B1 (en) Vaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases
Zhu et al. A bacteriophage-based, highly efficacious, needle-and adjuvant-free, mucosal COVID-19 vaccine
JP6808650B2 (ja) 短縮型ロタウイルスｖｐ４タンパク質およびその適用
Ludlow Respiratory syncytial virus infection in the modern era
JP7844442B2 (ja) ヒトサイトメガロウイルスワクチン
TWI901715B (zh) 大猩猩腺病毒核酸及胺基酸序列，包含彼之載體，及其用途
AU2021290231A1 (en) Arthrogenic alphavirus vaccine
JP2010535504A5 (enExample)
CN116688110A (zh) 犬特应性皮炎的治疗
KR20180038557A (ko) 타겟 폴리펩티드를 제시하기 위한 폴리펩티드 캐리어 및 이의 용도
CN118076646A (zh) 一种可诱导广谱中和活性重组多组分新冠病毒三聚体蛋白疫苗的制备及应用
JP7317796B2 (ja) 呼吸器疾患を治療するための方法および組成物
CN117295516A (zh) 用于治疗hsv的疫苗组合物和方法
JP2014534262A5 (enExample)